GSK plc (NYSE:GSK) Receives $43.25 Consensus PT from Analysts

GSK plc (NYSE:GSK - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten research firms that are covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold rating and three have given a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $43.25.

Several equities analysts have commented on the stock. Barclays upgraded shares of GSK to a "hold" rating in a research report on Tuesday, August 27th. Jefferies Financial Group cut shares of GSK from a "buy" rating to a "hold" rating and cut their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Argus upgraded shares of GSK to a "strong-buy" rating in a research note on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday.

GSK Stock Up 1.0 %

GSK stock traded up $0.35 during midday trading on Monday, hitting $33.70. The stock had a trading volume of 8,801,339 shares, compared to its average volume of 4,105,554. The business has a 50-day moving average of $39.08 and a two-hundred day moving average of $40.68. The firm has a market cap of $69.84 billion, a price-to-earnings ratio of 21.66, a price-to-earnings-growth ratio of 1.29 and a beta of 0.66. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK has a 52-week low of $32.83 and a 52-week high of $45.92.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be given a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a yield of 4.66%. The ex-dividend date of this dividend is Friday, November 15th. This is an increase from GSK's previous quarterly dividend of $0.38. GSK's payout ratio is currently 98.70%.

Insider Buying and Selling at GSK

In other news, major shareholder Plc Gsk bought 2,791,930 shares of the firm's stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares of the company's stock, valued at $134,205,528. This trade represents a 19.97 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.00% of the stock is currently owned by company insiders.

Institutional Trading of GSK

Institutional investors and hedge funds have recently made changes to their positions in the business. Blair William & Co. IL raised its position in GSK by 14.9% during the first quarter. Blair William & Co. IL now owns 23,493 shares of the pharmaceutical company's stock worth $1,007,000 after acquiring an additional 3,044 shares during the period. TIAA Trust National Association acquired a new stake in GSK in the 1st quarter worth about $302,000. O Shaughnessy Asset Management LLC increased its stake in GSK by 10.7% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 136,740 shares of the pharmaceutical company's stock worth $5,862,000 after buying an additional 13,201 shares in the last quarter. Arjuna Capital raised its holdings in shares of GSK by 2.6% during the first quarter. Arjuna Capital now owns 32,078 shares of the pharmaceutical company's stock valued at $1,375,000 after acquiring an additional 825 shares during the last quarter. Finally, Lake Street Advisors Group LLC lifted its position in shares of GSK by 44.1% in the first quarter. Lake Street Advisors Group LLC now owns 7,737 shares of the pharmaceutical company's stock valued at $335,000 after acquiring an additional 2,366 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.